Autoimmune events during interferon beta-1b treatment for multiple sclerosis-Reference-Cited by-同舟云学术

Autoimmune events during interferon beta-1b treatment for multiple sclerosis

Published:1999-01 Issue:1 Volume:162 Page:74-83
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Durelli L,Ferrero B,Oggero A,Verdun E,Bongioanni M.R,Gentile E,Isoardo G.L,Ricci A,Rota E,Bergamasco B,Durazzo M,Saracco G,Biava M.A,Brossa P.C,Giorda L,Pagni R,Aimo G

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference69 articles.

1. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection;Alexander;Lancet,1987

2. Frequency of anti-nuclear antibodies in multiple sclerosis;Barned;Neurology,1995

3. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon;Burman;J Clin Endocrinol Metab,1988

4. Cirelli R, Herne KB, McCrary ML, Tyring SK. Adverse effects of interferons. In: Reder AT, editor. Interferon therapy of multiple sclerosis. New York: Dekker, 1997:445–478.

5. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b;Dayal;Neurology,1995

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon;Frontiers in Endocrinology;2022-08-05

2. Thyropathies iatrogènes;Les Maladies de la Thyroïde;2022

3. Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial;International Immunopharmacology;2021-08

4. Comparing Expression of OAS-RNaseL Pathway-Related Genes in SARS-CoV-2 and Similar Viruses;2021-04-30

5. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis;Drug Safety;2019-03-04